Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Programmed death I (PD-1), an inhibitory receptor on immune system cells, has long been known to play an important dual role in immune regulation: Preventing the immune system from attacking the self ...

Since its discovery in the 1990s, “programmed cell death protein 1,” or PD-1, has been regarded as a leading target in cancer treatments. A “checkpoint” receptor that often resides on the surface of ...

programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that often resides on the surface of immune system cells, the PD-1 molecule ...

A 3-D image shows a T cell expressing the immune checkpoint receptor PD-1 (green) interacting with an antigen presenting cell expressing the ligand PD-L1 (magenta).

PD-L1 is a cell surface receptor expressed on both tumour and regulatory ... given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...

Advanced Renal Cell Carcinoma (RCC) WELIREG is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...